Cannabinoids, inflammation, and fibrosis
Cannabinoids apparently act on inflammation through mechanisms different from those of agents such as non-steroidal anti-inflammatory drugs (NSAIDs). As a class, the cannabinoids are generally free from the adverse effects associated with NSAIDs. Their clinical development thus provides a new approach to treatment of diseases characterised by acute and chronic inflammation and fibrosis. Thus, several cannabinoids may be considered candidates for development as anti-inflammatory and anti-fibrotic agents.